Follow for more talkers

Promising new way of detecting sepsis early in babies and pregnant women

A breakthrough study by Irish researchers pinpointed a biomarker for the early identification of the potentially deadly condition.

Avatar photo

Published

on
(Photo by Jimmy Conover via Unsplash)

By Stephen Beech

A "promising" new way of detecting sepsis early in newborn babies and pregnant women has been discovered.

A breakthrough study by Irish researchers pinpointed a biomarker for the early identification of the potentially deadly condition in "high-risk" patient groups, including young children.

The team discovered the potential of the molecule interleukin-6, known as IL-6, as a powerful indicator of sepsis which results from the immune system’s overreaction to infection.

It is one of the leading causes of loss of life around the world, accounting for an estimated 11 million deaths every year.

Young children, especially those under five years old, and pregnant women are considered "highly vulnerable" due to immunological changes and increased susceptibility.

However, diagnosing sepsis during pregnancy is difficult as physiological changes can obscure its early signs.

(Photo by CDC on Unsplash)

However, scientists say prompt diagnosis is critical due to the non-specific symptoms of sepsis and the limitations of traditional diagnostic biomarkers, such as C-reactive protein (CRP) and procalcitonin (PCT), which have delayed responses.

Given the rapid progression of sepsis, they emphasized there is an urgent need for biomarkers that offer faster, more accurate diagnosis to enable timely treatment.

The new study analyzed serial blood samples from 252 patients with suspected sepsis.

They were classified by infection type - bacterial, viral, or no infection - and physiological response - normal, systemic inflammatory response syndrome, sepsis and septic shock.

Diagnostic accuracy was evaluated ranging from 1.0, a perfect test with 100% specificity and sensitivity, to 0.5, a completely ineffective test.

IL-6 "consistently outperformed" traditional biomarkers in distinguishing bacterial from non-bacterial infections, with values of 0.91 in children, 0.94 in maternal patients, and 0.86 in newborn babies.

Researchers say IL-6 also "effectively" stratified sepsis severity, distinguishing between mild infection, sepsis, and septic shock, a critical capability for guiding timely and appropriate treatment.

In terms of sensitivity and specificity, IL-6 exceeded 80% in both pediatric and maternal patients, detecting bacterial infections with 91% sensitivity in children and 94% in pregnant women.

In newborns, while IL-6 maintained high specificity (97.1%), its sensitivity (67.6%) was lower.

(Photo by Eduardo Barrios via Unsplash)

The research team said the lower sensitivity may be partly attributable to the complexities of diagnosing neonatal sepsis, where there is no clear consensus definition.

They added that a broader spectrum of presentations in neonatal sepsis may also contribute to the differences.

The researchers highlighted the advantages of IL-6 over traditional biomarkers.

Study lead author Dr. Sean Whelan, a specialist registrar in clinical microbiology currently working in Galway University Hospital, said: “IL-6 secretion rises within one to two hours, peaks at six hours and decreases by 24 hours, whereas CRP and PCT peak much later at 48 and 24 hours, respectively.

"This faster, steeper response makes IL-6 a promising biomarker for earlier sepsis detection.”

Dr. Whelan also highlighted its growing clinical application.

'(Photo by Lazaro Rodriguez Jr via Pexels)

He said: “IL-6 is already in routine use in our institutions, the Rotunda Hospital and Children’s Health Ireland at Temple Street, Dublin, for these populations.

"The challenges to wider adoption have been lessened by the development of commercially available testing on commonly used platforms, which can provide real-time results.

"The COVID-19 pandemic accelerated this process, as IL-6 testing became more widely used in assessing patient inflammation.”

He added: “Our findings reinforce the potential of IL-6 as a promising biomarker in sepsis diagnosis.

“With wider adoption and in combination with clinical assessment, IL-6 could significantly improve clinical decision-making and support timely, targeted treatment for high-risk patients.”

The findings were presented at the annual Congress of the European Society of
 Clinical Microbiology and Infectious Diseases (ESCMID Global) in Vienna, Austria.

Stories and infographics by ‘Talker Research’ are available & ready to use. Stories and videos by ‘Talker News’ are managed by Talker Inc. For queries, please submit an inquiry via our contact form.

Top Talkers